262 related articles for article (PubMed ID: 26697891)
21. A Single-Dose Crossover Pharmacokinetic Comparison Study of Oral, Rectal and Topical Quetiapine in Healthy Adults.
Leung JG; Nelson S; Cunningham JL; Thompson VH; Bobo WV; Kung S; Dierkhising RA; Plevak MF; Lapid MI
Clin Pharmacokinet; 2016 Aug; 55(8):971-6. PubMed ID: 26873228
[TBL] [Abstract][Full Text] [Related]
22. Development of In Vitro-In Vivo Correlation for Potassium Chloride Extended Release Tablet Formulation Using Urinary Pharmacokinetic Data.
Mittapalli RK; Marroum P; Qiu Y; Apfelbaum K; Xiong H
Pharm Res; 2017 Jul; 34(7):1527-1533. PubMed ID: 28512718
[TBL] [Abstract][Full Text] [Related]
23. Self-reported sedation profile of quetiapine extended-release and quetiapine immediate-release during 6-day initial dose escalation in bipolar depression: a multicenter, randomized, double-blind, phase IV study.
Riesenberg RA; Baldytcheva I; Datto C
Clin Ther; 2012 Nov; 34(11):2202-11. PubMed ID: 23059166
[TBL] [Abstract][Full Text] [Related]
24. In Vitro Dissolution as a Tool for Formulation Selection: Telmisartan Two-Step IVIVC.
Ruiz Picazo A; Martinez-Martinez MT; Colón-Useche S; Iriarte R; Sánchez-Dengra B; González-Álvarez M; García-Arieta A; González-Álvarez I; Bermejo M
Mol Pharm; 2018 Jun; 15(6):2307-2315. PubMed ID: 29746133
[TBL] [Abstract][Full Text] [Related]
25. Time Scaling for In Vitro-In Vivo Correlation: the Inverse Release Function (IRF) Approach.
Cardot JM; Lukas JC; Muniz P
AAPS J; 2018 Aug; 20(6):95. PubMed ID: 30159772
[TBL] [Abstract][Full Text] [Related]
26. Approach to Evaluating QT Prolongation of Quetiapine Fumarate in Late Stage of Clinical Development Using Concentration-QTc Modeling and Simulation in Japanese Patients With Bipolar Disorder.
Fukushi R; Nomura Y; Katashima M; Komatsu K; Sato Y; Takada A
Clin Ther; 2020 Aug; 42(8):1483-1493.e1. PubMed ID: 32792252
[TBL] [Abstract][Full Text] [Related]
27. Development and internal validation of an in vitro-in vivo correlation for a hydrophilic metoprolol tartrate extended release tablet formulation.
Eddington ND; Marroum P; Uppoor R; Hussain A; Augsburger L
Pharm Res; 1998 Mar; 15(3):466-73. PubMed ID: 9563079
[TBL] [Abstract][Full Text] [Related]
28. Development of in vitro - in vivo correlations for newly optimized Nimesulide formulations.
Hanif M; Shoaib MH; Yousuf RI; Zafar F
PLoS One; 2018; 13(8):e0203123. PubMed ID: 30169547
[TBL] [Abstract][Full Text] [Related]
29. Novel extended IVIVC combined with DoE to predict pharmacokinetics from formulation compositions.
Lim JY; Kim TH; Song CH; Kim DH; Shin BS; Shin S
J Control Release; 2022 Mar; 343():443-456. PubMed ID: 35124130
[TBL] [Abstract][Full Text] [Related]
30. Quantitation of the impact of CYP3A5 A6986G polymorphism on quetiapine pharmacokinetics by simulation of target attainment.
Shilbayeh SA; Sy SK; Melhem M; Zmeili R; Derendorf H
Clin Pharmacol Drug Dev; 2015 Sep; 4(5):387-94. PubMed ID: 27137148
[TBL] [Abstract][Full Text] [Related]
31. Influence of stereoselective pharmacokinetics in the development and predictability of an IVIVC for the enantiomers of metoprolol tartrate.
Sirisuth N; Eddington ND
Pharm Res; 2000 Aug; 17(8):1019-25. PubMed ID: 11028951
[TBL] [Abstract][Full Text] [Related]
32. Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjects.
Datto C; Berggren L; Patel JB; Eriksson H
Clin Ther; 2009 Mar; 31(3):492-502. PubMed ID: 19393840
[TBL] [Abstract][Full Text] [Related]
33. 4β-Hydroxycholesterol level significantly correlates with steady-state serum concentration of the CYP3A4 substrate quetiapine in psychiatric patients.
Gjestad C; Haslemo T; Andreassen OA; Molden E
Br J Clin Pharmacol; 2017 Nov; 83(11):2398-2405. PubMed ID: 28585378
[TBL] [Abstract][Full Text] [Related]
34. In Vitro-In Vivo Correlation for Desvenlafaxine Succinate Monohydrate Extended Release Tablets.
da Silva JD; de Sousa VP; Cabral LM; Davanço MG; Meulman J; de Oliveira Carvalho P; Campos DR
AAPS PharmSciTech; 2020 Jul; 21(5):195. PubMed ID: 32666354
[TBL] [Abstract][Full Text] [Related]
35. Development and validation of an in vitro-in vivo correlation for buspirone hydrochloride extended release tablets.
Takka S; Sakr A; Goldberg A
J Control Release; 2003 Feb; 88(1):147-57. PubMed ID: 12586512
[TBL] [Abstract][Full Text] [Related]
36. Analysis of level A in vitro-in vivo correlations for an extended-release formulation with limited bioavailability.
Kakhi M; Marroum P; Chittenden J
Biopharm Drug Dispos; 2013 Jul; 34(5):262-77. PubMed ID: 23097186
[TBL] [Abstract][Full Text] [Related]
37. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
38. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
[TBL] [Abstract][Full Text] [Related]
39. Analysis of potentially predictive factors of efficacy of adjunct extended-release quetiapine fumarate in patients with major depressive disorder.
Bauer M; Thase ME; Liu S; Earley W; Eriksson H
J Psychopharmacol; 2015 May; 29(5):565-74. PubMed ID: 25257148
[TBL] [Abstract][Full Text] [Related]
40. Population pharmacokinetic modeling of quetiapine after administration of seroquel and seroquel XR formulations to Western and Chinese patients with schizophrenia, schizoaffective disorder, or bipolar disorder.
Zhou D; Bui KH; Li J; Al-Huniti N
J Clin Pharmacol; 2015 Nov; 55(11):1248-55. PubMed ID: 25975812
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
